Vanessa Carle - Jul 31, 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Secretary
Signature
/Vanessa Carle/
Stock symbol
LEXX
Transactions as of
Jul 31, 2024
Transactions value $
-$10,268
Form type
4
Date filed
8/1/2024, 12:25 PM
Previous filing
May 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LEXX common shares Sale -$10.3K -2.57K -100% $4.00 0 Jul 31, 2024 Direct
holding LEXX common shares 2.57K Jul 31, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LEXX Warrants 67 Jul 31, 2024 Common Shares 67 $36.00 Direct
holding LEXX Stock Options 12.6K Jul 31, 2024 Common Shares 12.5K $3.00 Direct F1
holding LEXX Stock Options 17.6K Jul 31, 2024 Common Shares 5K $3.00 Direct F2
holding LEXX Stock Options 27.6K Jul 31, 2024 Common Shares 10K $3.00 Direct F3
holding LEXX Stock Options 40.1K Jul 31, 2024 Common Shares 12.5K $2.91 Direct
holding LEXX Stock Options 50.1K Jul 31, 2024 Common Shares 10K $1.15 Direct
holding LEXX Stock Options 60.1K Jul 31, 2024 Common Shares 10K $2.36 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.31 pursuant to shareholder approval received May 9,2023
F2 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received May 9, 2023